|Videos|September 10, 2017

How Do Officials Test if Drugs Are Counterfeit or Not?

Milena McLaughlin, PharmD, MSc, explains how officials test if a drug is counterfeit or active.

Milena McLaughlin, PharmD, MSc, Assistant Professor, Pharmacy Practice, Midwestern University and Northwestern Memorial Hospital, explains how officials test if a drug is counterfeit or active.

Interview Transcript (slightly modified for readability):

“They’ll take a tablet and break it in half and actually rub it across [a] card, and then put that in water, and they can actually see, based on a reaction and the colors that come up on the card, if it’s actually an active medication or not. And so, that can tell them if there’s an active drug in the tablet. However, it can’t tell them how much active drug is in the tablet, so they’re also working on seeing quantitatively how much drug is in there as well.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.